**To the Editor**We read with interest an article entitled "Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentration in a Hemodialysis Patient" by Suzuki et al. in the Internal Medicine Advanced publication ([@B1]). The authors carefully described the clinical course of a patient who suffered from encephalopathy, possibly caused by ceftriaxone. The authors carefully deduced the causes of encephalopathy, most of which were highly inductive.

A previous pharmacokinetic study revealed lower serum concentrations of ceftriaxone among hemodialysis patients ([@B2]) in comparison to the concentration recorded in this patient (\>100 μg/mL) ([@B1]). Additionally, the cerebrospinal concentration (10.2 μg/mL) of ceftriaxone in this encephalopathic patient was higher in comparison to meningitis patients (median 3.52 μg/mL), whose blood-brain barrier might be more permeable, allowing medicines to penetrate more easily from blood into the cerebrospinal fluid ([@B3]). Thus, high serum and cerebrospinal fluid concentrations might explain ceftriaxone\'s pathogenicity.

However, these facts cannot clarify the definite cause of encephalopathy, because her symptoms and her serum concentration did not show a directly linear relationship ([@B1]). That is, she had no consciousness disturbance, despite the high concentration of ceftriaxone on day 9 after administration of this third-generation cephaorosporin. We would like to ask the authors why she did not show any neurological symptoms when the concentration of the drug was higher.
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